Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species

Publisher： Bentham Science Publishers

E-ISSN： 1874-0758|1|2|153-161

ISSN： 1872-3128

Source： Drug Metabolism Letters, Vol.1, Iss.2, 2007-04, pp. : 153-161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 10, 2007-10 ,pp. : 1062-1069

Bentham Science Publishers

Access to resources Recommend Favorite

Histone deacetylase inhibitors: novel anticancer agents

By Saunders N.A.   Popa C.   Serewko M.M.   Jones S.J.   Dicker A.J.   Dahler A.L.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1611-1621

Informa Healthcare

Access to resources Recommend Favorite

Romidepsin: a novel histone deacetylase inhibitor for cancer

By Bertino Erin M   Otterson Gregory A  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1151-1158

Informa Healthcare

Access to resources Recommend Favorite

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

By Duvic Madeleine   Vu Jenny  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-07 ,pp. : 1111-1120

Informa Healthcare

Access to resources Recommend Favorite

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl- XL

By Hwang Jung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1434-1442

Springer Publishing Company

Access to resources Recommend Favorite